Tenapanor not checked

Ardelyx · RDX5791 · AZD1722

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
2 active
16 in total
Targets
 

What this is

How it works
Sodium-Hydrogen Exchanger 3 Inhibitor FDA class
How it’s given
“Patients will receive tenapanor 50 mg BID (total of 100 mg daily)”In the company’s words, NCT07382167 on ClinicalTrials.gov
Tested for
Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome With Constipation (IBS-C)
Main trialPhase 3
“This is a 26-week, multi-center, randomized, double-blind, placebo-controlled study with a 4-week treatment-free Safety Follow-up period to assess the safety and efficacy of tenapanor (5 mg, 25mg, and 50 mg) in adult patients with Chronic Idiopathic Constipation (CIC) when administered twice daily for 26 consecutive weeks.”In the company’s words, NCT07382167 on ClinicalTrials.gov
Other names
IBSRELA · RDX5791 · AZD1722 · KHK7791

Other drugs for Irritable Bowel Syndrome With Constipation (IBS-C)

All 3 drugs for Irritable Bowel Syndrome With Constipation (IBS-C)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials16

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 26 Feb 2027 A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
Phase 3Enrolling by invitation Jul 2031 Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
Phase 4Completed 26 Jun 2021 A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
Phase 4Completed 13 Oct 2021 Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
Phase 3Completed 15 Nov 2019 A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
Phase 3Completed 10 Aug 2021 Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
Phase 3Completed 27 Sep 2021 Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
Phase 3Completed 1 Dec 2021 Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis
Phase 3Completed 27 Jun 2022 Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
Phase 3Completed 20 Aug 2026 Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
Phase 2/3Completed 17 Jul 2019 Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
Phase 2Completed 26 Nov 2019 A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD
Phase 2Completed 3 Dec 2019 Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients
Phase 2Completed 10 Dec 2019 Dose-finding Study of KHK7791 in Hyperphosphatemia Patients
Phase 2Completed 7 Jul 2026 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
Phase 1Completed 30 May 2024 An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Tenapanor

Following is part of Solo: you see every change to Tenapanor the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in